- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07663903
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
A Single-arm, Open-label, Multicenter Phase III Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-demand Treatment in Patients With Severe Hemophilia A (Adults and Adolescents) .
The indication for this product is to control bleeding in patients with hemophilia A (congenital deficiency of factor VIII).
The primary objective:
Evaluation of the efficacy of recombinant human coagulation factor VIII-Fc fusion protein for injection (FRSW107) as an on-demand treatment in previously treated patients with severe hemophilia A.
Secondary objectives:
Evaluation of the safety and immunogenicity of FRSW107 as an on-demand therapy in previously treated patients with severe hemophilia A.
Evaluate the on-demand treatment's PK profile of FRSW107 in previously treated patients with severe hemophilia A based on population pharmacokinetic (PopPK) methods ; preliminarily investigate the exposure-response (E-R) relationship of FRSW107 on-demand treatment in these patients if data permit.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Fuyang, Kina
- Fuyang Hospital, Affiliated to Anhui Medical University
-
Fuzhou, Kina
- Fujian Medical University Union Hospital
-
Ganzhou, Kina
- Ganzhou People's Hospital
-
Guangzhou, Kina
- Nanfang Hospital of Southern Medical University
-
Hefei, Kina
- Anhui Provincial Hospital
-
Huai'an, Kina
- Huai'an Second People's Hospital
-
Jinan, Kina
- Jinan Central Hospital
-
Kunming, Kina
- The Second Affiliated Hospital of Kunming Medical University
-
Nanning, Kina
- The First Affiliated Hospital of Guangxi Medical University
-
Nantong, Kina
- Affiliated Hospital of Nantong University
-
Nanyang, Kina
- The First Affiliated Hospital of Nanyang Medical College
-
Qinghai, Kina
- Qinghai Provincial People's Hospital
-
Rizhao, Kina
- Rizhao People's Hospital
-
Shijiazhuang, Kina
- The Second Hospital of Hebei Medical University
-
Taiyuan, Kina
- The Second Hospital of Shanxi Medical University
-
Tangshan, Kina
- North China University of Science and Technology Affiliated Hospital
-
Wenzhou, Kina
- Wenzhou People's Hospital
-
Wuhan, Kina
- Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology.
-
Wuxi, Kina
- Affiliated Hospital of Jiangnan University
-
Xi'an, Kina
- Xi'an Central Hospital
-
Yangzhou, Kina
- Subei People's Hospital of Jiangsu province
-
Zhengzhou, Kina
- Henan Cancer Hospital
-
Zhengzhou, Kina
- Zhengzhou People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina
- Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusive Criteria:
- Males aged 12 or younger to 65 years old.
- Patients clinically diagnosed with severe hemophilia A, i.e., those confirmed through screening or previous medical records: FⅧ Activity < 1%.
- Previous records confirm receipt of any recombinant and/or blood-derived coagulation factor VIII products or cold precipitate products, with a treatment of ≥150 exposure days (EDs ≥150).
- The participants have fully understood and been informed of this study, signed the informed consent form, and voluntarily enrolled in the clinical trial. The trial participants and/or their guardians are capable of cooperating with the hemostatic treatment and have the ability to complete all study procedures.
Exclusion Criteria:
- Known or suspected allergy to the investigational drug or its excipients, including mouse or hamster proteins;
- Hypersensitivity or anaphylaxis after FⅧ or IgG2 injection in the past;
- FⅧ inhibitor positive (≥0.6 BU/mL) during the screening period, or have a history of FⅧ inhibitor positive in the past, or a family history of FⅧ inhibitor positive;
- Von Willebrand factor (vWF) antigen test results were lower than the lower limit of normal value;
- Severe anemia at the screening stage (hemoglobin < 60 g/L);
- Platelet count during screening period < 100×109 /L;
Abnormal liver function:
.Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) >3 times upper limit of normal (ULN); or Serum total bilirubin (TBIL) >1.5x ULN;
Patients with abnormal renal function:
Creatinine clearance (Ccr) <50 ml/min (according to Cockcroft and Gault formula); or Serum creatinine (Cr) >1.5x ULN;
- People with active hepatitis C, that is, hepatitis C virus (HCV) antibody positive and HCV RNA positive; Or anti-treponema pallidum specific antibody (TPHA) positive; Or positive for antibodies against the human immunodeficiency virus (HIV);
- Patients with coagulation dysfunction other than hemophilia A;
- Have a medical condition that may increase the risk of bleeding;
- A history of drug or alcohol abuse;
- Have a known mental disorder that may affect trial compliance;
- Patients who have received transfusions of blood or blood components within 4 weeks prior to screening;
- Participants who had participated in other clinical trials within 1 month before screening;
- Use of any anticoagulant or antiplatelet drugs, off-label maximum dose of non-steroidal anti-inflammatory drugs (NSAID) within 7 days prior to screening; Or patients who need to be treated with anticoagulant or antiplatelet drugs or off-label maximum doses of SAID during clinical trials;
- Severe cardiovascular and cerebrovascular disease or major thromboembolic events, such as stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association [NYHA] grade ≥ III), and severe arrhythmias (including QTc interphase > 480 ms, corrected by Fridericia formula), uncontrolled hypertension (systolic ≥ 160 mmHg or diastolic ≥100 mmHg), deep vein thrombosis, etc.
- Study patients who had used emesezumab within 6 months prior to first administration of the drug;
- Patients who had used monoclonal antibody therapy, Fc fusion protein products (except FRSW107 and FRSW117), PEG products (except FRSW117), or intravenous immunoglobulin infusion within 3 months before the first administration of the investigational drug;
- Study patients who underwent major surgery within 3 months prior to initial drug administration (major surgery is defined in 6.2.3 Perioperative management);
- Study patients who have used FⅧ preparation of any standard half-life (e.g., Bycoch, Coproch, Biinidin, Renjie, NoL, Antaine, etc.) within 3 days or 5 half-lives prior to first administration of the drug (taking the elderly); Patients who have used any other extended half-life preparation FⅧ within 4 days or 5 half-lives prior to first dosing (for the elderly);
- Study patients with fever, severe active bacterial or viral infection, and allergies within 2 weeks before the first administration of the drug;
- Systemic immunomodulators (such as glucocorticoids [> 10 mg/ day equivalent dose of prednisone], alpha-interferon, immunoglobulin, cyclophosphamide, cyclosporin, etc.) used within 14 days prior to the first administration of the study drug or planned during the study period were allowed to be inhaled, nasal spray, or topical corticosteroids;
- Those who had been vaccinated within 4 weeks prior to initial administration of the study drug; Or who plan to be vaccinated during PK blood collection (only for subjects in the PK subgroup);
- Plan to have a child or sperm donation during the entire trial period and within 3 months after the last dose, or do not want to use effective physical contraception (such as condoms, diaphragms, Iuds, etc.);
- Have other serious medical conditions that the researchers said could not benefit from them
- Subjects deemed unsuitable by other investigators.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: On-demand Treatment.
On-demand treatment (recommended range: 20-50 IU/kg)
|
Treatment for 6 months as needed.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The haemostatic effective rate
Tidsramme: 6 months
|
The haemostatic effect of FRSW107 when used for treatment of bleeds, assessed on a four-point scale for haemostatic response (excellent, good, moderate and none) by counting excellent and good as success and moderate and none as failure.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of infusions and IU/kg of FRSW107 needed for the treatment of bleeding episodes
Tidsramme: 6 months
|
6 months
|
|
|
FVIII activity during on-demand: activity recovery rate
Tidsramme: Visit1,Day1
|
FVIII activity recovery rate on Day1's haemostatic therapy.
|
Visit1,Day1
|
|
Hemophilia Joint Health Score (HJHS 2.1) during on-demand treatment
Tidsramme: 6 month
|
total score and each subscale score of HJHS 2.1, as well as their changes over time.
|
6 month
|
|
incidence of lack of drug efficacy
Tidsramme: 6 months
|
Lack of drug efficacy is defined as: during on-demand treatment, hemostatic efficacy is assessed as "ineffective" or "poor/no response" following two consecutive administrations within 72 hours for the same bleeding episode. incidence of lack of drug efficacy=number of lack of drug efficacy/number of evaluated treatment*100%. |
6 months
|
|
Occurrence of AEs and SAEs
Tidsramme: 6 month
|
6 month
|
|
|
Incidence rate of positive FVIII inhibitors
Tidsramme: 6 month
|
A positive FⅧ inhibitor is defined as a Bethesda inhibitor titer ≥ 0.6 BU/mL.
Incidence rate of positive FVIII inhibitors=number of positive FⅧ inhibitors participant / total number of trial participants *100%.
|
6 month
|
|
Incidence rate of positive ADA, Incidence rate of positive anti-CHO antibody
Tidsramme: 6 month
|
Incidence rate of positive ADA=number of positive ADA participant / total number of trial participants *100% Incidence rate of positive anti-CHO antibody=number of positive anti-CHO antibody participant / total number of trial participants *100%
|
6 month
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: Renchi Yang, PhD, Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SS-107-III05
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .